EE658 Budget Impact Analysis for Multi-Indication Targeted Therapy: A Case Study of Cabozantinib Cost-Saving in Algeria as Treatment Option in First-Line & Second-Line Renal-Cell Carcinoma and Second-Line Hepatocellular Carcinoma

Saved in:
Bibliographic Details
Published in:Value in health 2022-12, Vol.25 (12), p.S186-S186
Main Authors: Belouizdad, M, Guesmi, K, Oulmane, N, Kezzal, N, Abed, N, Stamboul, S, Touafek, N
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1098-3015
1524-4733
DOI:10.1016/j.jval.2022.09.897